Faris Khan, MD
Cardiovascular Disease · Omaha, NENPI 1245493246
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,875 of the $17,263 with a category attached, or 80.4%. Medical Device Business Services, Inc. accounts for 80.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $9,109 and has fallen 92.6% since, to $672 in 2025.
Across 45 payments — averaging $383.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$14K
- Abbott$2K
- Medtronic$460
- Biosense Webster, Inc.$393
- Boston Scientific$295
- Philips North America LLC$124
What the payments were for
- Consulting fees$13,87580%
- Travel & lodging$1,5459%
- Food & beverage$1,84211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 8 | $13,875 |
| Abbott | 11 | $2,116 |
| Medtronic(2 entities) | 11 | $460 |
| Biosense Webster, Inc. | 4 | $393 |
| Boston Scientific | 3 | $295 |
| Philips North America LLC | 8 | $124 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$14,022
- AVEIR$1,808
- Carto 3 System$235
- AURORA EV-ICD MRI SURESCAN$166
- OCTARAY MAPPING CATHETER$147
- NUVISION ICE CATHETER$147
- LINQ II$145
- VIEWMATE$135
- Farapulse$134
How this compares
$17,263 in reported general payments places this provider in the 85th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 377 | $368,862 |
| XareltoRivaroxaban | 46 | $57,891 |
| JardianceEmpagliflozin | 46 | $39,544 |
| EntrestoSacubitril/Valsartan | 27 | $37,179 |
| Dofetilide | 90 | $23,191 |
| Flecainide Acetate | 26 | $1,477 |
| SotalolSotalol Hcl | 31 | $1,327 |
| Metoprolol Succinate | 123 | $1,275 |
| Enoxaparin Sodium | 12 | $966 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 31 | $958 |
| Atorvastatin Calcium | 44 | $618 |
| Losartan Potassium | 36 | $563 |
| Carvedilol | 50 | $551 |
| Potassium Chloride | 16 | $478 |
| Metoprolol Tartrate | 69 | $443 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Omaha
- Ronald ZoltyOmaha$945K
- Jeffrey CarstensOmaha$124K
- John HenryOmaha$79K
- Joseph ThibodeauOmaha$75K
- Qais RadaidehOmaha$50K
- Edward OlearyOmaha$36K
- Michael PetersOmaha$13K
- Thomas PorterOmaha$11K
- Gregory PavlidesOmaha$10K
- Shiva PonamgiOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.